Made on
Tilda
How we put a $7.25B settlement call
on the record —
before the hearing that tests it
After its Supreme Court win, Bayer's $7.25B Roundup class settlement heads to a final-approval hearing on September 14, 2026. Every commentator is asking the same question: will the judge approve it? The objectors are loud, the opt-out mechanics have been called "comically difficult," and a federal judge had already called the earlier approval "filthy." The whole room is watching the bench.
We asked a different question — not what the court will do, but what Bayer will do: how committed it stays, what it concedes first if the court pushes back, and what would have to happen for it to walk away. We wrote our forecast down on 20 August 2026, before the hearing, and registered a timestamped, hashed copy on the Open Science Framework (OSF). Nothing below can be revised after the fact.
Frozen on 20 August 2026 and registered on OSF on 21 August 2026, before the hearing, ID SYSTEM put the following on the record:
Our forecast is that Bayer stays with the settlement. Court resistance on its own does not make it walk — what it is pursuing is a clean end to the future-claims tail, and it holds to the deal as long as that end remains reachable.
If the court pushes back, we expect Bayer to concede on structure rather than price — to change process and design before it raises the settlement amount.
Our forecast is that the future-claims subclass is the first major element Bayer is prepared to give up. After the Supreme Court's June 2026 ruling, that subclass — central to the settlement in February 2026 — had become largely redundant, which is why we expect it to be the first thing conceded if the court demands changes.
We do not expect the objections themselves to move Bayer. The development we expect to change its course is a structural ruling on the future-claims subclass, not the volume of objections around it.
Our forecast is that Bayer walks away only if the court strikes the future-claims subclass and refuses to let the rest of the settlement stand without it — the point at which the deal can no longer release future claims. It is the loss of that release, not a higher price, that would end its commitment.
Standard legal review answers whether the settlement is lawful and likely to be approved. It does not tell you what the company on the other side will do, or in what order it will give ground — a question that matters directly to litigation funders. That is what we set out on the record in advance.
Every claim above was fixed in writing before the hearing and sealed so its meaning cannot be edited after the outcome. From 14 September 2026, it can be checked against what Bayer actually does.
The forecast is narrow and specific. Bayer remains committed to the settlement and does not raise the amount to save it. If the court pushes back, we expect it to seek structural concessions first, and — if forced — to give up the future-claims subclass before anything else, the element the June 2026 Supreme Court ruling had already made largely redundant. Our forecast is that Bayer walks away only if the court strikes that subclass and refuses to sever it, so the settlement can no longer release future claims; court resistance short of that does not end its commitment.
The forecast does not predict the judge's ruling; it predicts Bayer's response to different forms of court resistance. It is a forecast about the company's own choices, and it stands or falls on its own.
The hearing is 14 September 2026; Bayer's actions will be assessed through 31 October 2026. The forecast is already fixed and dated — it will either match what Bayer does by that date or it won't, in public, on a clock we set before we could see the answer.
Legal review and diligence answer whether the documents hold up and whether the settlement is likely to be approved. We forecast something else: how the party across the table is likely to behave, set down in advance so it can be checked against what happens.
Those are different questions, and they give different answers — and it is the second one that tells a litigation funder how the matter is likely to move.
Public matter, publicly docketed (King v. Monsanto, 22nd Judicial Circuit, City of St. Louis, No. 2622-CC00325). A pre-outcome forecast dated 20 August 2026 and registered on the Open Science Framework (OSF) on 21 August 2026, before the 14 September 2026 fairness hearing, and assessed through 31 October 2026; the timestamped original is hashed and can be produced to verify the record. This is a forecast of decision-making, not legal or investment advice, and takes no position on the merits of the litigation.